News

Article

EMA Clarifies Position on Sputnik V European Approval Process

EMA has clarified its position on the European approval process of the Sputnik V vaccine.

The European Medicines Agency (EMA) has issued a statement, clarifying its position on the European approval process of the Sputnik V vaccine, which is being developed by the Gamaleya National Centre of Epidemiology and Microbiology in Russia.

According to a Feb. 10, 2021 press release, the regulatory body has asserted that, despite reports stating the contrary, it has not received an application for the rolling review or a marketing authorization of Sputnik V. EMA has provided the vaccine’s developers with scientific advice and is in dialogue with the developers regarding next steps.

Sputnik V developers have expressed an interest in submitting the vaccine for rolling review consideration—a process that can only be employed during emergency situations. However, EMA’s Committee for Medicinal Products for Human Use needs to agree that the vaccine is suitable to progress via the accelerated review procedure prior to submission of the application.

Furthermore, EMA emphasized in the statement that any new assessments of COVID-19 vaccines or medicines being undertaken by the agency would be promptly announced so that the public are informed. Therefore, if there has been no communication from EMA regarding a vaccine or medicine, then the status of that specific therapy remains unchanged.

Source: EMA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More